FrancophonIA/ELRC3.0 huggingface dataset:
English: Table 1: Lutetium (177Lu) principle radiation emission data
Croatian: Tablica 1.: Osnovni podaci o emisijama zračenja lutecija (177Lu)
English: EndolucinBeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients.
Croatian: EndolucinBeta je radiofarmaceutski prekursor i nije namijenjen za izravnu primjenu bolesnicima.
English: Excipient: Hydrochloric acid solution
Croatian: Pomoćna tvar: otopina kloridne kiseline
English: Only syringe needles (for example, non-metallic) with proven resistance to dilute acid should be used to minimise trace metal impurity levels.
Croatian: Kako bi se razina onečišćenja u obliku metala u tragovima smanjila na najmanju moguću mjeru, smiju se upotrebljavati samo igle za štrcaljke (primjerice nemetalne) koje su dokazano otporne na razrijeđenu kiselinu.
English: What you need to know before the medicine radiolabelled with EndolucinBeta is used The medicine radiolabelled with EndolucinBeta must not be used
Croatian: Što morate znati prije nego primite lijek koji je radioaktivno označen EndolucinBetom Lijek koji je radioaktivno označen EndolucinBetom ne smije se primjenjivati:
English: Each 10 mL vial contains an activity ranging from 8 - 150 GBq, corresponding to 1.936 micrograms of Lutetium (177Lu), at ART.
Croatian: Svaka bočica od 10 ml sadrži aktivnost u rasponu od 8 do 150 GBq što odgovara vrijednosti od 1,9 do 36 mikrograma lutecija (177Lu) pri ART-u.
English: Each 2 mL vial contains an activity ranging from 3 - 80 GBq, corresponding to 0.73 - 19 micrograms of Lutetium (177Lu), at ART.
Croatian: Svaka bočica od 2 ml sadrži aktivnost u rasponu od 3 do 80 GBq što odgovara vrijednosti od 0,73 do 19 mikrograma lutecija (177Lu) pri ART-u.
English: In all cases, the risk of the radiation is outweighed by the potential benefit of receiving the radiolabelled medicine.
Croatian: U svim slučajevima, moguća korist od primanja lijeka koji je radioaktivno označen nadmašuje rizik od zračenja.
English: How EndolucinBeta is stored
Croatian: Kako čuvati EndolucinBetu
English: The quantity of EndolucinBeta required for radiolabelling and the quantity of Lutetium (177Lu)-labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use.
Croatian: Količina EndolucinBete potrebna za radioaktivno označavanje i količina lijeka označenog lutecijem (177Lu) koja se naknadno primjenjuje ovisi o lijeku koji se radioaktivno označava i o njegovoj namjeni.
English: EndolucinBeta 40 GBq/mL radiopharmaceutical precursor, solution
Croatian: EndolucinBeta 40 GBq/ml radiofarmaceutski prekursor, otopina
English: - The active substance is Lutetium (177Lu) chloride.
Croatian: - Djelatna tvar je lutecijev (177Lu) klorid.
English: Myelosuppression
Croatian: Mijelosupresija
English: EXP: {DD/MM/YYYY, hh:00 CET}
Croatian: Rok valjanosti: {DD/MM/GGGG, ss:00 CET}
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING METALLIC CAN AND OUTER CARTON
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU METALNA LIMENKA I VANJSKA KUTIJA
English: Radiolabelled somatostatin analogues are excreted by the kidney.
Croatian: Radioaktivno označeni analozi somatostatina izlučuju se bubrezima.
English: Gamma 208.3662 * mean energies are listed for beta particles Lutetium (177Lu) decays by emission of beta radiation to stable Hafnium (177Hf).
Croatian: * za beta čestice navedene su srednje vrijednosti energija Lutecij (177Lu) se emisijom beta zračenja raspada u stabilni hafnij (177Hf).
English: The nuclear medicine doctor will inform you if you need to take any special precautions after receiving the medicine radiolabelled with EndolucinBeta.
Croatian: Nakon primjene lijeka koji je radioaktivno označen EndolucinBetom, morate Liječnik nuklearne medicine obavijestit će vas o tome trebate li poduzeti određene posebne mjere opreza nakon primanja lijeka koji je radioaktivno označen EndolucinBetom.
English: Dry mouth has been reported among patients with metastatic castration resistant prostate cancer receiving PSMA-targeted Lutetium (177Lu)-labelled radioligands and has been transient.
Croatian: U bolesnika s metastatskim karcinomom prostate rezistentnim na kastraciju koji su primali lutecijem (177Lu)-označene radioligande usmjerene na PSMA zabilježena su suha usta, no to je bilo prolazno.
English: For more information, refer to the package leaflet of the particular medicinal product to be radiolabelled.
Croatian: Više informacija potražite u uputi o lijeku za konkretni lijek koji se radioaktivno označava.
English: EndolucinBeta must be used only in combination with another medicine (carrier medicine) which has been specifically developed and authorised for being combined with Lutetium (177Lu) chloride.
Croatian: Primjena lijeka koji je radioaktivno označen EndolucinBetom i provedba postupka EndolucinBeta smije se primjenjivati samo u kombinaciji s drugim lijekom (lijekom nosačem) koji je posebno razvijen i odobren za kombinaciju s lutecijevim (177Lu) kloridom.
English: Lutetium (177Lu) emits β-particles of moderate maximum energy (0.498 MeV) with a maximum tissue penetration of approximately 2 mm. Lutetium (177Lu) also emits low-energy γ-rays which allow scintigraphic, biodistribution and dosimetry studies with the same Lutetium (177Lu)-labelled medicinal products.
Croatian: Lutecij (177Lu) također emitira γ-zrake niske energije što omogućuje scintigrafijska, biodistribucijska i dozimetrijska ispitivanja s istim lijekovima označenim lutecijem (177Lu).
English: Management should be in accordance with local protocols.
Croatian: Zbrinjavanje treba biti sukladno važećim protokolima.
English: 1 mL of solution contains 40 GBq of Lutetium (177Lu) chloride at activity reference time (ART).
Croatian: 1 ml otopine sadrži 40 GBq lutecijeva (177Lu) klorida u vrijeme umjeravanja aktivnosti (ART).
English: 1 mL sterile solution contains 40 GBq Lutetium (177Lu) chloride on the activity reference time (corresponding to 10 micrograms of Lutetium (177Lu) as Lutetium (177Lu) chloride).
Croatian: 1 ml sterilne otopine sadrži 40 GBq lutecijeva (177Lu) klorida u vrijeme umjeravanja aktivnosti (što odgovara 10 mikrograma lutecija (177Lu) u obliku lutecijeva (177Lu) klorida).
English: Such information will be supplied in the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Croatian: Takve su informacije navedene u sažetku opisa svojstava lijeka/uputi o lijeku onog lijeka koji se radioaktivno označava.
English: EndolucinBeta 40 GBq/mL radiopharmaceutical precursor, solution Lutetium (177Lu) chloride
Croatian: EndolucinBeta 40 GBq/ml radiofarmaceutski prekursor, otopina lutecijev (177Lu) klorid
English: If you get any side effects, talk to your nuclear medicine doctor.
Croatian: Ako imate bilo kakvih pitanja, obratite se svom liječniku nuklearne medicine.
English: Blood and lymphatic system disorders: very common: Anaemia, thrombocytopenia, leukopenia and lymphopenia Endocrine disorders: not known: Carcinoid crisis
Croatian: Vrlo često: anemija, trombocitopenija, leukopenija i limfopenija
English: Cases of hepatotoxicity have been reported in the post-marketing setting and in the literature in patients with liver metastases undergoing treatment with Lutetium (177Lu) peptide receptor radionuclide therapy for neuroendocrine tumours.
Croatian: Nakon stavljanja lijeka u promet i u literaturi zabilježeni su slučajevi hepatotoksičnosti u bolesnika s metastazama u jetri liječenima peptidnom radionuklidnom terapijom lutecijem (177Lu) zbog neuroendokrinih tumora.
English: 1 mL of solution contains 40 GBq Lutetium (177Lu) chloride on activity reference time (ART), corresponding to 10 micrograms of Lutetium (177Lu) (as chloride).
Croatian: 1 ml otopine sadrži 40 GBq lutecijeva (177Lu) klorida u vrijeme umjeravanja aktivnosti (engl. activity reference time, ART) što odgovara vrijednosti od 10 mikrograma lutecija (177Lu) (u obliku lutecijeva klorida).
English: Common (may affect up to 1 in 10 people): - Bone marrow cancer (myelodysplastic syndrome) Uncommon (may affect up to 1 in 100 people): - Bone marrow cancer (acute myeloid leukaemia) Not known (frequency cannot be estimated from the available data): - Carcinoid crisis - Tumour lysis syndrome (rapid breakdown of tumour cells) Bone marrow cancer (myelodysplastic syndrome and acute myeloid leukaemia) has been reported in patients several years after treatment with Lutetium (177Lu) peptide receptor radionuclide therapy for neuroendocrine tumours.
Croatian: Često (mogu se javiti u do 1 na 10 osoba): - rak koštane srži (mijelodisplastični sindrom) Manje često (mogu se javiti u do 1 na 100 osoba): - rak koštane srži (akutna mijeloična leukemija)
English: Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) have been observed after treatment with Lutetium (177 Lu) peptide receptor radionuclide therapy for neuroendocrine tumours
Croatian: Mijelodisplastični sindrom i akutna mijeloična leukemija Mijelodisplastični sindrom (MDS) i akutna mijeloična leukemija (AML) uočeni su nakon peptidne radionuklidne terapije lutecijem (177 Lu) (engl.
English: Dry mouth has been reported among patients with prostate cancer receiving treatment with Lutetium (177Lu) and has been temporary.
Croatian: U bolesnika s karcinomom prostate koji su primali terapiju lutecijem (177Lu) zabilježna su suha usta, no to je bilo privremeno.
English: - if you are allergic to Lutetium (177Lu) chloride or any of the other ingredients of this medicine
Croatian: - ako ste alergični na lutecijev (177Lu) klorid ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.); - ako ste trudni ili smatrate da biste mogli biti trudni.
English: Please refer to the package leaflet of the medicine that is to be radiolabelled with EndolucinBeta.
Croatian: Pogledajte uputu o lijeku koji treba biti radioaktivno označen EndolucinBetom.
English: Small Intestine Stomach Wall ULI Wall
Croatian: Stijenka donjeg dijela debelog crijeva Tanko crijevo
English: How the medicine radiolabelled with EndolucinBeta is used
Croatian: Kako primjenjivati lijek koji je radioaktivno označen EndolucinBetom
English: Effects on ability to drive and to use machines following treatment by Lutetium (177Lu)-labelled medicinal products will be specified in the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Croatian: Informacije o utjecaju na sposobnost upravljanja vozilima i rad sa strojevima nakon liječenja lijekovima koji su označeni lutecijem (177Lu) navedene su u sažetku opisa svojstava lijeka/uputi o lijeku koji se radioaktivno označava.
English: Please read the package leaflet of that medicine.
Croatian: Pogledajte sažetak opisa svojstava lijeka.
English: Thymus
Croatian: Gama
English: Ovaries
Croatian: Jajnici
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING LEAD POT
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU OLOVNI SPREMNIK
English: EndolucinBeta is not to be administered directly to patients.
Croatian: EndolucinBeta ne smije se primijeniti izravno bolesnicima.
English: EndolucinBeta should not be administered directly to the patient.
Croatian: EndolucinBeta ne smije se primijeniti izravno bolesniku.
English: Colourless type I glass 2 mL or 10 mL vial with a V-shaped and flat bottom, respectively, with a bromobutyl stopper, closed with an aluminium seal.
Croatian: Bezbojna bočica (staklo tipa I) od 2 ml ili od 10 ml s ravnim dnom u obliku slova
English: Tumour lysis syndrome has been reported following Lutetium (177Lu) radioligand therapy.
Croatian: Nakon radioligandne terapije lutecijem (177Lu) prijavljen je sindrom lize tumora.
English: Individual benefit/risk justification
Croatian: Procjena omjera koristi i rizika kod pojedinog bolesnika
English: EndolucinBeta must not be used after the expiry date and time which is stated on the label after EXP. EndolucinBeta will be stored in the original package that provides protection from radiation.
Croatian: EndolucinBeta se ne smije upotrijebiti nakon isteka roka valjanosti i vremena navedenog na naljepnici iza oznake „Rok valjanosti“.
English: Radiation nephropathy has been reported following peptide receptor radionuclide therapy for neuroendocrine tumours using other radioisotopes.
Croatian: Nakon peptidne radionuklidne terapije s drugim radioizotopima kod liječenja neuroendokrinih tumora prijavljena je radijacijska nefropatija.
English: EndolucinBeta is not intended for direct use in patients.
Croatian: EndolucinBeta nije namijenjen za izravnu primjenu u bolesnika.
English: Therefore, Lutetium metal-ion toxicity of EndolucinBeta (177Lu)-labelled medicinal products can be excluded.
Croatian: Stoga se toksičnost lijekova označenih lutecijem (177Lu) s pomoću EndolucinBete, s obzirom na lutecijev metalni ion, može isključiti.
English: …GBq/vial
Croatian: AKTIVNOST: …GBq/bočica
English: Adverse reactions following the administration of a Lutetium (177Lu)-labelled medicinal product prepared by radiolabelling with EndolucinBeta will be dependent on the specific medicinal product being used.
Croatian: Moguće nuspojave nakon primjene lijekova označenih lutecijem (177Lu) koji su pripremljeni radioaktivnim označavanjem EndolucinBetom ovise o konkretnom lijeku koji se koristi.
English: Further information concerning the use of Lutetium (177Lu)-labelled medicinal products concerning fertility is specified in the Summary of Product Characteristics of the medicinal product to be radiolabelled.
Croatian: Dodatne informacije u pogledu plodnosti u vezi s uporabom lijekova označenih lutecijem (177Lu) navedene su u sažetku opisa svojstava lijeka koji se radioaktivno označava.
English: If you are pregnant Medicines radiolabelled with EndolucinBeta must not be administered if you are pregnant.
Croatian: Ako ste trudni, ne smijete primati lijekove koji su radioaktivno označeni EndolucinBetom.
English: The following preparations must be available in medical institutions, which use EndolucinBeta for labelling of carrier molecules for therapeutic purposes: - Ca-DTPA (Trisodium calcium diethylenetriaminepentaacetate) or - Ca-EDTA (Calcium disodium ethylenediaminetetraacetate)
Croatian: - Ca-DTPA (trinatrijev kalcijev dietilentriaminpentaacetat) ili - Ca-EDTA (kalcijev dinatrijev etilendiamintetraacetat)
English: Dose reduction may be necessary in affected patients.
Croatian: U bolesnika u kojih nastane hepatotoksičnost možda će trebati sniziti dozu.
English: Treatment with Lutetium (177Lu) radioligand therapy may lead to the following side effects - a reduced number of red blood cells (anaemia) - a reduced number of platelets in the blood (thrombocytopenia) which are important to stop bleeding - a reduced number of white blood cells (leukopenia, lymphopenia or neutropenia) which are important for protecting the body against infection
Croatian: - smanjeni broj bijelih krvnih stanica (leukopenija, limfopenija ili neutropenija), koje su važne za zaštitu tijela od infekcija
English: Skin and subcutaneous tissue disorders: Alopecia, described as mild and temporary, has been observed among patients receiving Lutetium (177Lu) peptide receptor radionuclide therapy for neuroendocrine tumours.
Croatian: Poremećaji kože i potkožnog tkiva: U bolesnika koji su primali peptidnu radionuklidnu terapiju lutecijem (177Lu) za liječenje neuroendokrinih tumora zabilježena je alopecija, opisana kao blaga i privremena.
English: For information concerning special warnings and special precautions for use of Lutetium (177Lu)labelled medicinal products refer also to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Croatian: Više informacija o posebnim upozorenjima i mjerama opreza pri uporabi lijekova označenih lutecijem (177Lu) potražite i u Sažetku opisa svojstava lijeka/uputi o lijeku koji se radioaktivno označava.
English: What EndolucinBeta is and what it is used for What you need to know before the medicine radiolabelled with EndolucinBeta is used How the medicine radiolabelled with EndolucinBeta is used Possible side effects
Croatian: Što morate znati prije nego počnete primati lijek koji je radioaktivno označen EndolucinBetom Kako primjenjivati lijek koji je radioaktivno označen EndolucinBetom Moguće nuspojave
English: Refer to the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
Croatian: Pogledajte Sažetak opisa svojstava lijeka/uputu o lijeku za konkretni lijek koji se radioaktivno označava.
English: Package leaflet: Information for the patient EndolucinBeta 40 GBq/mL radiopharmaceutical precursor, solution
Croatian: Uputa o lijeku: Informacije za bolesnika EndolucinBeta 40 GBq/ml radiofarmaceutski prekursor, otopina lutecijev (177Lu) klorid
English: There could be effects on your ability to drive and to use machines due to the medicine used in combination with EndolucinBeta.
Croatian: Uporaba lijeka koji se koristi u kombinaciji s EndolucinBetom može utjecati na vašu sposobnost upravljanja vozilima i strojevima.
English: - If you get any side effects, talk to your nuclear medicine doctor.
Croatian: - Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika nuklearne medicine.
English: Gallbladder Wall LLI Wall
Croatian: Prsna žlijezda Štitna žlijezda
English: Muscle
Croatian: Pluća Mišić
English: The dosimetry estimates were based on a rat biodistribution study performed according to MIRD pamphlet no.16, and the calculations were performed using the OLINDA 1.1 software package.
Croatian: Dozimetrijske procjene temelje se na ispitivanju biodistribucije na štakorima sukladno brošuri MIRD
English: The pharmacokinetic properties of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with EndolucinBeta, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Croatian: Farmakokinetička svojstva lijekova označenih lutecijem (177Lu) koji su pripremljeni radioaktivnim označavanjem s EndolucinBetom, prije primjene, ovise o prirodi lijeka koji se radioaktivno označava.
English: The pharmacodynamic properties of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with EndolucinBeta, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Croatian: Farmakodinamička svojstva lijekova označenih lutecijem (177Lu) koji su pripremljeni radioaktivnim označavanjem s EndolucinBetom, prije primjene, ovise o prirodi lijeka koji se radioaktivno označava.
English: For information concerning interactions associated with the use of Lutetium (177Lu)-labelled medicinal products refer to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Croatian: Informacije o interakcijama povezanima s primjenom lijekova označenih lutecijem (177Lu) potražite u sažetku opisa svojstava lijeka/uputi o lijeku onog lijeka koji se radioaktivno označava.
English: Lot:
Croatian: Tel:.
English: If you are breast-feeding
Croatian: Ako ste trudni
English: There have been reports of extravasation of Lutetium (177Lu) labelled ligands in the post-marketing setting.
Croatian: Nakon stavljanja lijeka u promet prijavljeni su slučajevi ekstravazacije liganada obilježenih lutecijem (177Lu).
English: Liver
Croatian: Dojenje
English: For more information concerning paediatric use of Lutetium (177Lu)-labelled medicinal products refer to the Summary of Product Characteristics/package leaflet of the medicinal product to be radiolabelled.
Croatian: Pedijatrijska populacija Više informacija o pedijatrijskoj primjeni lijekova označenih lutecijem (177Lu) potražite u Sažetku opisa svojstava lijeka/uputi o lijeku koji se radioaktivno označava.
English: ANNEX IV SCIENTIFIC CONCLUSIONS AND GROUNDS FOR THE VARIATION TO THE TERMS OF THE MARKETING AUTHORISATION(S)
Croatian: Znanstveni zaključci Uzimajući u obzir PRAC-ovo izvješće o ocjeni periodičkog(ih) izvješća o neškodljivosti lijeka (PSUR)
English: Lungs
Croatian: Grudi
English: It is presented as a clear and colourless solution in a colourless type I glass 2 mL or 10 mL vial with a V-shaped and flat bottom, respectively, with a bromobutyl stopper, closed with an aluminium seal.
Croatian: U obliku je bistre i bezbojne otopine koja se nalazi u bezbojnoj bočici od stakla tipa
English: Metabolism and nutrition disorders: not known: Tumour lysis syndrome
Croatian: Nepoznato: Sindrom lize tumora
English: General warning
Croatian: Opće upozorenje
English: Urinary Bladder Wall Uterus
Croatian: Stijenka žučnog mjehura
English: The toxicological properties of Lutetium (177Lu)-labelled medicinal products prepared by radiolabelling with EndolucinBeta prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
Croatian: Toksikološka svojstva lijekova označenih lutecijem (177Lu) koji su pripremljeni radioaktivnim označavanjem EndolucinBetom prije primjene ovise o prirodi lijeka koji se radioaktivno označava.
English: A. Before you start
Croatian: Prije nego li počnete
English: Wash your hands with soap and water.
Croatian: Operite ruke vodom i sapunom.
English: Date of first authorisation: 14 January 2016
Croatian: Datum prvog odobrenja: 14. siječanj 2016
English: Other information (please complete)
Croatian: Ostali podaci (molimo ispunite)
English: Do not warm in any other way.
Croatian: Nemojte je zagrijavati ni na koji drugi način.
English: • Do not recycle.
Croatian: • Nemojte reciklirati.
English: Find a well-lit, clean surface and gather all the equipment you need:
Croatian: Odaberite dobro osvijetljenu i čistu površinu i prikupite sve što Vam je potrebno:
English: There may be new information.
Croatian: Mogu sadržavati nove informacije.
English: The healthcare professional's educational material should contain the following key elements:
Croatian: Edukacijski materijal za zdravstvene djelatnike mora sadržavati sljedeće ključne elemente:
English: After the second click, count slowly to 15 to make sure that the injection is complete.
Croatian: Nakon drugog "klika" polako brojite do 15 kako biste bili sigurni da je injekcija potpuna.
English: Approximately half the cases were lymphomas.
Croatian: Otprilike polovica slučajeva bili su limfomi.
English: The device will click a second time.
Croatian: Začut će se "klik" po drugi put.
English: b Values for Disease Activity Score (DAS) are means.
Croatian: b Vrijednosti za bodove za aktivnost bolesti (Disease Activity Score (DAS) su srednje vrijednosti.
English: Please ask your doctor if you have any questions about this.
Croatian: Obratite se svom liječniku ako imate pitanja u vezi s time.
English: This is important to make the medicine easier and more comfortable to inject.
Croatian: Ovo je važno jer tako lijek postaje jednostavniji i ugodniji za injekciju.
English: This appearance is normal for Benepali.
Croatian: Ovakav izgled je normalan za Benepali.
English: Continuous therapy beyond 24 weeks may be appropriate for some adult patients (see section 5.1).
Croatian: Kontinuirana terapija duža od 24 tjedna može biti prikladna za neke odrasle bolesnike (vidjeti dio 5.1.).
English: Mean duration was approximately 3 to 5 days.
Croatian: Prosječno su trajale od 3 do 5 dana.
English: This Fc component contains the hinge, CH2 and CH3 regions, but not the CH1 region of IgG1.
Croatian: Ta Fc komponenta sadrži spojno mjesto, CH2 i CH3 regije, ali ne i regiju CH1 IgG1.
English: Benepali is a medicine that is made from two human proteins.
Croatian: Benepali je lijek napravljen od dva ljudska proteina.
English: • Infections/monitoring: Tell your doctor of any recent travel outside the European region.
Croatian: • Infekcije/praćenje: Obavijestite svog liječnika o svim nedavnim putovanjima izvan Europe.
English: The needle guard will completely cover the needle.
Croatian: Štitnik za iglu će u cijelosti pokriti iglu.
English: 2616 LR Delft The Netherlands
Croatian: 2616 LR Delft Nizozemska
English: 79 (75%)a sPGA “clear” or “minimal”, n (%)
Croatian: 79 (75%)a sPGA “čist” ili “minimalan”, n (%)
English: • The risk of opportunistic infections and tuberculosis (TB)
Croatian: • Rizik od razvoja oportunističkih infekcija i tuberkuloze (TBC)
English: If you use more Benepali than you should
Croatian: Ako primijenite više Benepalija nego što ste trebali